Cushing Syndrome, Diabetes, Endocrine Diseases, Metabolic Diseases, Obesity & Overweight, Sarcopenia, Sarcopenic Obesity
Conditions
Brief summary
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. .
Interventions
Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity
Sponsors
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Metabolic or endocrine disease
Exclusion criteria
* Known myopathy * Systemic steroid use (\> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome * Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol * History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of sarcopenia / sarcopenic obesity | From February 2026 to december 2056 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Myokines levels in serum or plasma | February 2026 to December 2056 | Myokines levels in serum or plasma as measured by ELISA |
| Myokine expression | February 2026 to December 2056 | Myokine expression in muscle as measured by RT-qPCR or RNA-Seq |
| Prevalence of MASLD | March 2026 to December 2056 | MASLD as evaluated by Fibroscan, based on controlled attenuation parameter (CAP, in decibels per meter) as a marker of hepatic steatosis |
| Prevalence of MASH | March 2026 to December 2056 | Prevalence of MASH as evaluated by Fibroscan, based on Liver stiffness measurement (LSM, in kilopascals) as a surrogate of liver fibrosis |
Countries
Belgium
Contacts
CONTACTLaura Orioli, MD, PhD
Outcome results
None listed